Artificial intelligence (AI)-aided analysis of pathology slides showed potential as a predictive biomarker for non-small cell ...

These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

Immunotherapy has transformed cancer treatment, offering new avenues of hope for patients with advanced disease or limited ...

The latest announcement is out from AstraZeneca ( (AZN) ).

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing ...

For decades, treating lung cancer has been like trying to hit a moving target in the dark. Just when doctors think they've found an effective treatment, the cancer adapts and escapes. Now, a team of ...

Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025.

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the ...

China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating ...

Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic ...

Achilles Therapeutics has sold certain technology assets to drug giant AstraZeneca for $12 million following a review of strategic alternatives by the clinical-stage biopharmaceutical company.